
GenSight Biologics Updates Real-World Data on LUMEVOQ® at NANOS 2024
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a prominent biopharmaceutical company specializing in innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, has disclosed recent prospective…












